Search
All Clinical Trials
A listing of 23101 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
4165 - 4176 of 23101
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Parkinson's Foundation PD GENEration Genetic Registry
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +55 locations
Conditions: Parkinson's Disease
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +89 locations
Conditions: High-risk Large B-cell Lymphoma (LBCL)
SilverCloud as a School-Based Intervention for Vulnerable Youth
Recruiting
The goal of this study is to test the efficacy and feasibility of a clinician-guided, app-based cognitive behavioral therapy (CBT) program, SilverCloud, as a school-based mental health intervention for vulnerable youth. An open trial of SilverCloud will be conducted to determine preliminary efficacy in this sample and inform program refinements by collecting outcome self-report assessments and conducting interviews on feasibility and acceptability. After the program and its implementation strate... Read More
Gender:
ALL
Ages:
Between 13 years and 22 years
Trial Updated:
05/16/2025
Locations: Rutgers University, New Brunswick, New Jersey +2 locations
Conditions: Depression, Anxiety
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Recruiting
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells.
This study will utilize a staggered enrollment design with a safety observation period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
Endometrial Cell Collection With the PadKit
Recruiting
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Jersey Shore University Medical Center, Neptune, New Jersey +1 locations
Conditions: Neoplasms
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +46 locations
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Recruiting
This study evaluates the feasibility and safety of a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Diffuse Large B-Cell Lymphoma
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Recruiting
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Recruiting
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Kingman Regional Medical Center, Kingman, Arizona +191 locations
Conditions: Cigarette Smoking-Related Carcinoma
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California +198 locations
Conditions: Systemic Lupus Erythematosus
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
Recruiting
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/16/2025
Locations: Atlanta VA Medical Center, Decatur, Georgia
Conditions: Alcohol Use Disorder, Hiv
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Recruiting
Background:
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/16/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
4165 - 4176 of 23101